×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

$15.94
+0.40 (+2.57%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.50
$15.97
50-Day Range
$14.22
$20.88
52-Week Range
$14.04
$25.66
Volume
301,022 shs
Average Volume
373,216 shs
Market Capitalization
$540.73 million
P/E Ratio
17.91
Dividend Yield
N/A
Beta
1.07
30 days | 90 days | 365 days | Advanced Chart
Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Collegium Pharmaceutical logo

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
152
Year Founded
N/A

Sales & Book Value

Annual Sales
$276.87 million
Cash Flow
$2.25 per share
Book Value
$5.78 per share

Profitability

Net Income
$71.52 million
Pretax Margin
-12.71%

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,451,000
Market Cap
$540.73 million
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

397th out of 1,424 stocks

Pharmaceutical Preparations Industry

161st out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -













Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

Is Collegium Pharmaceutical a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical
or view top-rated stocks.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Collegium Pharmaceutical
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.90 by $0.46. The specialty pharmaceutical company earned $83.80 million during the quarter, compared to the consensus estimate of $78.67 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 3.26% and a net margin of 15.68%. The company's quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 EPS.
View Collegium Pharmaceutical's earnings history
.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450.00 million-$465.00 million, compared to the consensus revenue estimate of $448.72 million.

What price target have analysts set for COLL?

4 Wall Street analysts have issued 1 year target prices for Collegium Pharmaceutical's stock. Their forecasts range from $26.00 to $42.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $33.25 in the next year. This suggests a possible upside of 108.6% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the following people:
  • Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph., Co-Founder & Chairman (Age 58, Pay $110k) (LinkedIn Profile)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 51, Pay $1.1M)
  • Ms. Colleen Tupper, Exec. VP & CFO (Age 46, Pay $631.24k)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 38, Pay $620.1k) (LinkedIn Profile)
  • Mr. Scott Dreyer, Exec. VP & Chief Commercial Officer (Age 49, Pay $591k) (LinkedIn Profile)
  • Dr. Richard Malamut, Exec. VP & Chief Medical Officer (Age 62, Pay $612.2k)
  • Ms. Alex Dasalla, Head of Investor Relations
  • Mr. Bart J. Dunn, Exec. VP of Strategy & Corp. Devel.
  • Ms. Marlo Manning, Head of HR
  • Mr. Scott Sudduth, Head of Technical Operations
What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.85%), Vanguard Group Inc. (6.80%), Principal Financial Group Inc. (4.18%), State Street Corp (3.86%), Renaissance Technologies LLC (3.74%) and Invesco Ltd. (2.98%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical
.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, South Dakota Investment Council, Qube Research & Technologies Ltd, Royce & Associates LP, Summit Global Investments, Peregrine Capital Management LLC, and Factorial Partners LLC.
View insider buying and selling activity for Collegium Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, State Street Corp, Principal Financial Group Inc., Russell Investments Group Ltd., Los Angeles Capital Management LLC, BlackRock Inc., Pacer Advisors Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for Collegium Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $15.94.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of $540.73 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or $0.889990 on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

Collegium Pharmaceutical employs 152 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.